Peptide LexiconAll compounds

Lixisenatide: The Gila-Monster GLP-1 Drug With Six Extra Lysines, Its Heart Trial and Its Parkinson's Result

Lixisenatide is a 44-amino-acid GLP-1 receptor agonist built from exendin-4, the peptide in Gila monster saliva, with one proline removed and six lysines added. In the US it is sold today inside Soliqua, a fixed mix with insulin glargine for type 2 diabetes. Its 6,068-patient heart trial found no increase or decrease in cardiovascular events, and a 2024 phase 2 trial reported slower motor decline in early Parkinson's disease.

FDA-approved (2016)GLP-1 receptor agonistType 2 diabetes only

Caroline S · Published 2026-11-18

Length

44 amino acids, C-terminal amide; C215H347N61O65S, molecular weight 4,858 (PubChem CID 90472060; label 4.8585 kDa)

Sequence

H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-I-E-W-L-K-N-G-G-P-S-S-G-A-P-P-S-K-K-K-K-K-K-NH2 — exendin-4 (1–39) without proline 38, plus six lysines (PubChem synonym 'DesPro38Exendin-4(1-39)-Lys6-NH2'; ChEBI)

Origin

Synthetic analogue of exendin-4 from the saliva of the Gila monster (Heloderma suspectum); Sanofi. Adlyxin approved 2016-07-27 (BLA 208471); Soliqua 100/33 approved 2016-11-21 (BLA 208673)

Last reviewed

2026-11-18

What is it good for?

Lowering blood sugar in adults with type 2 diabetes, alongside diet and exercise. In the US it is now found in Soliqua 100/33, a once-daily pen that combines it with the long-acting insulin glargine. Its heart-outcome trial showed it neither raised nor lowered cardiovascular events; a Parkinson's disease result is a single phase 2 trial, not an approved use.

Illustration: A complex, coiled molecular model in white and deep green on a white surface with a copper reflection.
Illustration

What it is

Lixisenatide is a GLP-1 receptor agonist — a peptide that switches on the same receptor as the gut hormone GLP-1. It is 44 amino acids long with an amide group at the end (Soliqua label; ChEBI), and PubChem records it as C215H347N61O65S, molecular weight 4,858 (CID 90472060).

It is built on exendin-4, a 39-amino-acid peptide from the saliva of the Gila monster (Heloderma suspectum). PubChem's systematic synonym spells out the two changes: "DesPro38Exendin-4(1-39)-Lys6-NH2" — proline 38 removed, and six lysines added to the tail:

Exendin-4 / exenatide Lixisenatide
Length 39 amino acids 44 amino acids
Residue 38 proline removed
Tail ends …P-P-S ends …P-P-S-K-K-K-K-K-K-NH2
Library entry exenatide this page

The other 38 residues are shared, which is why the two drugs are often grouped as the "exendin-based" GLP-1 agonists, apart from the human-based liraglutide and semaglutide.

How it works

The Soliqua label states the mechanism in one line: lixisenatide increases glucose-dependent insulin release, decreases glucagon secretion and slows gastric emptying. "Glucose-dependent" means the insulin effect is larger when blood sugar is high, which is the general property of the GLP-1 system and of the wider incretin family. In Soliqua its peak in blood comes 2.5 to 3 hours after the injection, and 55% of it is bound to plasma proteins (label section 12.3).

What the evidence shows

Blood sugar. Soliqua's current label leads with Study A (NCT05058147): 1,170 adults with type 2 diabetes on metformin, 30 weeks, open-label.

Arm Patients HbA1c start → end Change
Soliqua (glargine + lixisenatide) 469 8.1 → 6.5% −1.6
Insulin glargine alone 467 8.1 → 6.8% −1.3
Lixisenatide alone 233 8.1 → 7.3% −0.9

Read across the rows, lixisenatide on its own lowered HbA1c the least of the three arms; its role in this product is as an add-on to basal insulin.

The heart. ELIXA (NEJM 2015, PMID 26630143; funded by Sanofi) randomised 6,068 people with type 2 diabetes who had had a heart attack or unstable angina in the previous 180 days. Over a median 25 months the primary composite — cardiovascular death, heart attack, stroke or hospitalisation for unstable angina — occurred in 13.4% on lixisenatide and 13.2% on placebo (hazard ratio 1.02, 95% CI 0.89–1.17). That met the non-inferiority bound and failed superiority (P = 0.81); heart-failure admissions (HR 0.96) and deaths (HR 0.94) did not differ.

Parkinson's disease. LixiPark (NEJM 2024, PMID 38598572) gave daily lixisenatide or placebo to 156 people diagnosed with Parkinson's less than three years earlier. At 12 months the motor score (MDS-UPDRS part III) had changed by −0.04 points on the drug and +3.04 on placebo, a difference of 3.08 (95% CI 0.86–5.30, P = 0.007). Other secondary end points did not differ much, nausea occurred in 46% and vomiting in 13%, and the authors wrote that longer and larger trials are needed. It is one phase 2 trial; it does not make lixisenatide a Parkinson's treatment.

What is not established: any weight-management indication (none of its labels carries one), any cardiovascular benefit, and any disease-modifying effect in Parkinson's beyond this single trial.

Where it stands

Lixisenatide was approved in the US in 2016 — Adlyxin on 27 July (BLA 208471) and Soliqua 100/33 on 21 November (BLA 208673). On 2026-11-18 openFDA held a current Soliqua label (effective 2026-03-18) and no Adlyxin label; this entry does not infer from that why. Soliqua's label limits it to adults with type 2 diabetes and states that combining it with any other product containing a GLP-1 receptor agonist is not recommended. Its warnings include anaphylaxis, pancreatitis, hypoglycaemia, acute kidney injury from fluid loss, severe gastrointestinal reactions, gallbladder disease and pulmonary aspiration under anaesthesia.

The library's insulin entry covers the other half of Soliqua; pramlintide is another peptide given alongside insulin.

Sources opened 2026-11-18: Soliqua 100/33 label (openFDA, effective 2026-03-18: sections 1, 2, 5, 6, 11, 12, 14); Drugs@FDA records for BLA 208471 and BLA 208673; PubChem CID 90472060 (properties, ChEBI description, synonyms); Pfeffer 2015, NEJM (ELIXA, PMID 26630143, abstract); Meissner 2024, NEJM (LixiPark, PMID 38598572, abstract); PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Lowers HbA1c in type 2 diabetes

Soliqua label, Study A (NCT05058147): 1,170 randomised for 30 weeks; HbA1c −1.6% on Soliqua, −1.3% on insulin glargine, −0.9% on lixisenatide alone

Is safe for the heart after a coronary event

ELIXA, NEJM 2015 (PMID 26630143): 6,068 patients after acute coronary syndrome, median 25 months; events 13.4% v 13.2% on placebo, hazard ratio 1.02 (0.89–1.17) — non-inferior, not superior

Slows Parkinson's disease

LixiPark, NEJM 2024 (PMID 38598572): phase 2, 156 people with early disease, 12 months; motor score −0.04 v +3.04 on placebo (difference 3.08, P = 0.007); nausea 46%

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Approved 2016 as Adlyxin (BLA 208471) and in Soliqua 100/33 (BLA 208673, label effective 2026-03-18). openFDA holds a current label for Soliqua but none for Adlyxin (2026-11-18).

Trials

ClinicalTrials.gov: 80 studies name lixisenatide (2026-11-18).

Published record

PubMed: 739 records with lixisenatide in the title or abstract, 95 tagged as randomised controlled trials (2026-11-18).

Frequently asked questions

What is lixisenatide?

A GLP-1 receptor agonist: a 44-amino-acid peptide that acts like the gut hormone GLP-1 to raise insulin release when blood sugar is high, lower glucagon and slow stomach emptying. It is made from exendin-4, a peptide first found in Gila monster saliva.

How is lixisenatide different from exenatide?

Both come from exendin-4. Exenatide is exendin-4 itself, 39 amino acids. Lixisenatide removes one proline near the end and adds a tail of six lysines, giving 44 amino acids.

What is Soliqua?

A once-daily pen that combines insulin glargine and lixisenatide in a fixed ratio — 100 units of insulin to 33 mcg of lixisenatide per mL. Its label is for adults with type 2 diabetes, and it is not to be used with any other GLP-1 drug.

Does lixisenatide protect the heart?

Its heart trial, ELIXA, found no difference: major cardiovascular events occurred in 13.4% on lixisenatide and 13.2% on placebo over a median 25 months. That showed the drug did not raise heart risk, but it did not show a benefit.

Is lixisenatide used for Parkinson's disease?

Not as an approved use. A 2024 phase 2 trial in 156 people with early Parkinson's found less worsening of motor scores over a year than placebo, and its authors called for longer and larger trials. Nausea was common.

Is lixisenatide used for weight loss?

It is not approved for weight loss. Its labels cover blood-sugar control in type 2 diabetes only; the weight-management approvals in this area belong to other drugs, covered in the library's semaglutide and tirzepatide entries.